Thorsten Bach1, Felix Wölbling2, Andreas J Gross3, C Netsch3, S Tauber4, Tobias Pottek5, Christian Wülfing6, Claus Brunken4. 1. Department of Urology, Asklepios Hospital Harburg, Eissendorfer Pferdeweg 52, 21075, Hamburg, Germany. t.bach@asklepios.com. 2. Department of Urology, Asklepios Hospital Harburg, Eissendorfer Pferdeweg 52, 21075, Hamburg, Germany. 3. Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. 4. Department of Urology, Asklepios Hospital St. Georg, Hamburg, Germany. 5. Department of Urology, Asklepios Westklinkum Rissen, Hamburg, Germany. 6. Department of Urology, Asklepios Hospital Altona, Hamburg, Germany.
Abstract
PURPOSE: TUR-prostate (TUR-P) is considered the reference method for surgical treatment of benign prostatic obstruction (BPO); Greenlight laser photoselective vaporization (PVP) and thulium laser vapoenucleation (ThuVEP) have also been established as treatments of BPO. Objective of this prospective observation was to compare a large numbers of patients treated in everyday routine. METHODS: This prospective multicentre data collection assesses morbidity and perioperative course of consecutive men treated with BPO-related transurethral surgery between 2011 and 2014 in a German metropolis area with TUR-P, PVP or ThuVEP. RESULTS: Two thousand six hundred and forty-eight patients have been treated in the time period. All treatment options achieved immediate improvement of voiding parameters. Multivariate analyses proved shorter hospital stay after laser treatments as compared to resection (p < 0.001). In terms of hospital stay, the advantage of ThuVEP compared to TUR-P increased with prostate volume (p < 0.001). Patients with ongoing anticoagulation or bridging had prolonged hospital stay (p < 0.001). Overall adverse events were least frequent in PVP (p 0.016), as were Clavien 3b events (p < 0.001). CONCLUSIONS: Surgical treatment of BPO is effective and safe independent of the surgical procedure. Volume reduction is most effective in ThuVEP; PVP has the lowest rate of severe complications. Laser treatment is associated with shorter hospital stay. Surgery under ongoing anticoagulation prolonged the post-operative hospital stay.
PURPOSE: TUR-prostate (TUR-P) is considered the reference method for surgical treatment of benign prostatic obstruction (BPO); Greenlight laser photoselective vaporization (PVP) and thulium laser vapoenucleation (ThuVEP) have also been established as treatments of BPO. Objective of this prospective observation was to compare a large numbers of patients treated in everyday routine. METHODS: This prospective multicentre data collection assesses morbidity and perioperative course of consecutive men treated with BPO-related transurethral surgery between 2011 and 2014 in a German metropolis area with TUR-P, PVP or ThuVEP. RESULTS: Two thousand six hundred and forty-eight patients have been treated in the time period. All treatment options achieved immediate improvement of voiding parameters. Multivariate analyses proved shorter hospital stay after laser treatments as compared to resection (p < 0.001). In terms of hospital stay, the advantage of ThuVEP compared to TUR-P increased with prostate volume (p < 0.001). Patients with ongoing anticoagulation or bridging had prolonged hospital stay (p < 0.001). Overall adverse events were least frequent in PVP (p 0.016), as were Clavien 3b events (p < 0.001). CONCLUSIONS: Surgical treatment of BPO is effective and safe independent of the surgical procedure. Volume reduction is most effective in ThuVEP; PVP has the lowest rate of severe complications. Laser treatment is associated with shorter hospital stay. Surgery under ongoing anticoagulation prolonged the post-operative hospital stay.
Authors: Alexander Bachmann; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; J Andrew Thomas Journal: Eur Urol Date: 2013-11-11 Impact factor: 20.096
Authors: Vincenzo Serretta; Giuseppe Morgia; Luigi Fondacaro; Gaetano Curto; Antonio Lo bianco; Domenico Pirritano; Darwin Melloni; Fausto Orestano; Mario Motta; Michele Pavone-Macaluso Journal: Urology Date: 2002-10 Impact factor: 2.649
Authors: Sascha A Ahyai; Peter Gilling; Steven A Kaplan; Rainer M Kuntz; Stephan Madersbacher; Francesco Montorsi; Mark J Speakman; Christian G Stief Journal: Eur Urol Date: 2010-06-11 Impact factor: 20.096
Authors: Jean-Nicolas Cornu; Sascha Ahyai; Alexander Bachmann; Jean de la Rosette; Peter Gilling; Christian Gratzke; Kevin McVary; Giacomo Novara; Henry Woo; Stephan Madersbacher Journal: Eur Urol Date: 2014-06-25 Impact factor: 20.096
Authors: S Cimino; S Voce; F Palmieri; V Favilla; T Castelli; S Privitera; R Giardina; G Reale; G I Russo; G Morgia Journal: Int J Impot Res Date: 2017-08-17 Impact factor: 2.896